Update on sentinel lymph node biopsy for early-stage vulvar cancer

Brian Slomovitz, Robert L. Coleman, Maaike H M Oonk, Ate Van Der Zee, Charles Levenback

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Two prospective, multicenter clinical trials have demonstrated the feasibility and reproducibility of sentinel lymph node (SLN) biopsy as part of the standard management of early-stage vulvar carcinoma. On the basis of the results of these trials, many gynecologic oncologists have incorporated SLN biopsy for vulvar cancer into their practice. Studies have further shown that SLN biopsy is associated with better quality of life than full lymphadenectomy, is more cost-effective than full lymphadenectomy, and improved pathologic evaluation. A large observational study is currently evaluating the outcomes of patients with early-stage vulvar cancer according to the results of their SLN biopsy and the approach to their care; this study may confirm that full inguinofemoral lymphadenectomy is no longer necessary in most patients with this disease. Here, we review the published data supporting SLN biopsy as part of the standard of care for women with early-stage vulvar cancer and discuss future considerations for the management of this disease.

Original languageEnglish (US)
Pages (from-to)472-477
Number of pages6
JournalGynecologic Oncology
Volume138
Issue number2
DOIs
StatePublished - Aug 1 2015

Fingerprint

Vulvar Neoplasms
Sentinel Lymph Node Biopsy
Lymph Node Excision
Standard of Care
Disease Management
Multicenter Studies
Observational Studies
Quality of Life
Clinical Trials
Carcinoma
Costs and Cost Analysis

Keywords

  • Lymphoscintigraphy
  • Sentinel lymph node biopsy
  • Ultrastaging
  • Vulvar cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Slomovitz, B., Coleman, R. L., Oonk, M. H. M., Van Der Zee, A., & Levenback, C. (2015). Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecologic Oncology, 138(2), 472-477. https://doi.org/10.1016/j.ygyno.2015.05.017

Update on sentinel lymph node biopsy for early-stage vulvar cancer. / Slomovitz, Brian; Coleman, Robert L.; Oonk, Maaike H M; Van Der Zee, Ate; Levenback, Charles.

In: Gynecologic Oncology, Vol. 138, No. 2, 01.08.2015, p. 472-477.

Research output: Contribution to journalArticle

Slomovitz, B, Coleman, RL, Oonk, MHM, Van Der Zee, A & Levenback, C 2015, 'Update on sentinel lymph node biopsy for early-stage vulvar cancer', Gynecologic Oncology, vol. 138, no. 2, pp. 472-477. https://doi.org/10.1016/j.ygyno.2015.05.017
Slomovitz, Brian ; Coleman, Robert L. ; Oonk, Maaike H M ; Van Der Zee, Ate ; Levenback, Charles. / Update on sentinel lymph node biopsy for early-stage vulvar cancer. In: Gynecologic Oncology. 2015 ; Vol. 138, No. 2. pp. 472-477.
@article{cdcace1af96f40529cf9548fefecb2f1,
title = "Update on sentinel lymph node biopsy for early-stage vulvar cancer",
abstract = "Two prospective, multicenter clinical trials have demonstrated the feasibility and reproducibility of sentinel lymph node (SLN) biopsy as part of the standard management of early-stage vulvar carcinoma. On the basis of the results of these trials, many gynecologic oncologists have incorporated SLN biopsy for vulvar cancer into their practice. Studies have further shown that SLN biopsy is associated with better quality of life than full lymphadenectomy, is more cost-effective than full lymphadenectomy, and improved pathologic evaluation. A large observational study is currently evaluating the outcomes of patients with early-stage vulvar cancer according to the results of their SLN biopsy and the approach to their care; this study may confirm that full inguinofemoral lymphadenectomy is no longer necessary in most patients with this disease. Here, we review the published data supporting SLN biopsy as part of the standard of care for women with early-stage vulvar cancer and discuss future considerations for the management of this disease.",
keywords = "Lymphoscintigraphy, Sentinel lymph node biopsy, Ultrastaging, Vulvar cancer",
author = "Brian Slomovitz and Coleman, {Robert L.} and Oonk, {Maaike H M} and {Van Der Zee}, Ate and Charles Levenback",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.ygyno.2015.05.017",
language = "English (US)",
volume = "138",
pages = "472--477",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Update on sentinel lymph node biopsy for early-stage vulvar cancer

AU - Slomovitz, Brian

AU - Coleman, Robert L.

AU - Oonk, Maaike H M

AU - Van Der Zee, Ate

AU - Levenback, Charles

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Two prospective, multicenter clinical trials have demonstrated the feasibility and reproducibility of sentinel lymph node (SLN) biopsy as part of the standard management of early-stage vulvar carcinoma. On the basis of the results of these trials, many gynecologic oncologists have incorporated SLN biopsy for vulvar cancer into their practice. Studies have further shown that SLN biopsy is associated with better quality of life than full lymphadenectomy, is more cost-effective than full lymphadenectomy, and improved pathologic evaluation. A large observational study is currently evaluating the outcomes of patients with early-stage vulvar cancer according to the results of their SLN biopsy and the approach to their care; this study may confirm that full inguinofemoral lymphadenectomy is no longer necessary in most patients with this disease. Here, we review the published data supporting SLN biopsy as part of the standard of care for women with early-stage vulvar cancer and discuss future considerations for the management of this disease.

AB - Two prospective, multicenter clinical trials have demonstrated the feasibility and reproducibility of sentinel lymph node (SLN) biopsy as part of the standard management of early-stage vulvar carcinoma. On the basis of the results of these trials, many gynecologic oncologists have incorporated SLN biopsy for vulvar cancer into their practice. Studies have further shown that SLN biopsy is associated with better quality of life than full lymphadenectomy, is more cost-effective than full lymphadenectomy, and improved pathologic evaluation. A large observational study is currently evaluating the outcomes of patients with early-stage vulvar cancer according to the results of their SLN biopsy and the approach to their care; this study may confirm that full inguinofemoral lymphadenectomy is no longer necessary in most patients with this disease. Here, we review the published data supporting SLN biopsy as part of the standard of care for women with early-stage vulvar cancer and discuss future considerations for the management of this disease.

KW - Lymphoscintigraphy

KW - Sentinel lymph node biopsy

KW - Ultrastaging

KW - Vulvar cancer

UR - http://www.scopus.com/inward/record.url?scp=84938215060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938215060&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2015.05.017

DO - 10.1016/j.ygyno.2015.05.017

M3 - Article

VL - 138

SP - 472

EP - 477

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -